iRadimed (IRMD) vs PROCEPT BioRobotics (PRCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iRadimed (IRMD) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 11.7% versus a loss of 48.5%. Over five years, IRMD leads with a +134.2% price change compared with -58.9% for PRCT. iRadimed is the larger company by market cap ($1.10 billion vs $1.02 billion), about 1.1 times the size.
iRadimed pays a dividend yielding 0.90%, while PROCEPT BioRobotics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRMD | PRCT |
|---|---|---|
| Share price | $85.88 | $17.90 |
| Market cap | $1.10B | $1.02B |
| 1-day change | +0.48% | -0.06% |
| YTD return | -11.72% | -43.10% |
| 1-year return | +11.72% | -48.49% |
| 5-year return | +134.20% | -58.92% |
| P/E ratio (TTM) | 47.71 | — |
| Forward P/E | 35.01 | — |
| EPS (TTM) | $1.80 | $-1.94 |
| Dividend yield | 0.90% | 0.00% |
| Annual dividend | $0.77 | $0.00 |
| 52-week high | $107.90 | $38.11 |
| 52-week low | $71.34 | $16.67 |
| Distance from 52-week high | -20.41% | -53.03% |
| Analyst consensus | none | hold |
| Avg. price target upside | +37.40% | +25.25% |
| Average volume | 125.83K | 1.44M |
| Shares outstanding | 12.79M | 56.92M |
| Employees | 166 | 888 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRMD has outperformed PRCT by 60.2 percentage points over the past year.
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Health Care · Medical/Dental Instruments · 166 employees
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Health Care · Medical/Dental Instruments · 888 employees
IRMD vs PRCT FAQ
Which is bigger, iRadimed or PROCEPT BioRobotics?
iRadimed (IRMD) is larger, with a market capitalization of $1.10B compared with $1.02B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, IRMD or PRCT?
IRMD returned +11.72% over the past 12 months, compared with -48.49% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, iRadimed or PROCEPT BioRobotics?
iRadimed pays a dividend yielding 0.90%, while PROCEPT BioRobotics does not currently pay a regular dividend.
Are iRadimed and PROCEPT BioRobotics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.